This database contains 11 studies, archived under the term: "enzymology"
Click here to filter this large number of results.
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Portelius, Erik,
Zetterberg, Henrik,
Dean, Robert A.,
Marcil, Alexandre,
Bourgeois, Philippe,
Nutu, Magdalena,
Andreasson, Ulf,
Siemers, Eric,
Mawuenyega, Kwasi G.,
Sigurdson, Wendy C.,
May, Patrick C.,
Paul, Steven M.,
Holtzman, David M.,
Blennow, Kaj,
Bateman, Randall J.
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Greater responsiveness to donepezil in Alzheimer patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study
Kasuya, Masashi,
Meguro, Kenichi,
Okamura, Nobuyuki,
Funaki, Yoshihito,
Ishikawa, Hiroyasu,
Tanaka, Naofumi,
Iwata, Ren,
Yanai, Kazuhiko
The aim of the study was to predict donepezil responders among patients with Alzheimer disease (AD) based on cognitive tests and positron emission tomography. The Mini-Mental State Examination, Digit Symbol subtest (DigSm) of Wechsler Adult Intelligence Scale Revised, and Trail-Making Test A were administered for 80 patients with AD to assess global function, attention, and […]
A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteers after high protein meat diet: relationship to the methylation cycle
Zellner, Maria,
Babeluk, Rita,
Jakobsen, Lene H.,
Gerner, Christopher,
Umlauf, Ellen,
Volf, Ivo,
Roth, Erich,
Kondrup, Jens
Studies investigating the impact of high meat intake on cognition have yielded contradictory results as some show improved cognitive performance, whereas others report an increase of risk factors for dementia. However, few studies were designed to directly assess the effect of a high protein (HP) diet on both cognitive performance and corresponding biochemical parameters. A […]
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg, Agneta,
Darreh-Shori, Taher,
Peskind, Elaine,
Soininen, Hilkka,
Mousavi, Malahat,
Eagle, Gina,
Lane, Roger
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]
ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
Steinacker, Petra,
Klafki, Hans,
Lehnert, Stefan,
Jesse, Sarah,
Arnim, Christine A. F. V.,
Tumani, Hayrettin,
Pabst, Alice,
Kretzschmar, Hans A.,
Wiltfang, Jens,
Otto, Markus
The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. Unfortunately, none of the currently known markers are suited for screening or seems to be directly related to the pathophysiological process. A marker fulfilling these criteria might facilitate the early […]
A pilot study of yogic meditation for family dementia caregivers with depressive symptoms: effects on mental health, cognition, and telomerase activity
Lavretsky, H.,
Epel, E.S.,
Siddarth, P.,
Nazarian, N.,
Cyr, N. St.,
Khalsa, D.S.,
Lin, J.,
Blackburn, E.,
Irwin, M.R.
Background: This study examined the effects of brief daily yogic meditation on mental health, cognitive functioning, and immune cell telomerase activity in family dementia caregivers with mild depressive symptoms.; Methods: Thirty-nine family dementia caregivers (mean age 60.3 years old (SD = 10.2)) were randomized to practicing Kirtan Kriya or listening to relaxation music for 12 […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]